ResMed Inc. Forecasted to Earn Q1 2025 Earnings of $1.94 Per Share (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Equities research analysts at Zacks Research increased their Q1 2025 EPS estimates for shares of ResMed in a report issued on Monday, April 8th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $1.94 per share for the quarter, up from their prior forecast of $1.93. The consensus estimate for ResMed’s current full-year earnings is $7.45 per share. Zacks Research also issued estimates for ResMed’s FY2025 earnings at $8.04 EPS and FY2026 earnings at $8.65 EPS.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Wednesday, January 24th. The medical equipment provider reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.81 by $0.07. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.15 billion. ResMed had a net margin of 19.77% and a return on equity of 23.86%. The business’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.66 EPS.

A number of other equities research analysts have also commented on RMD. Royal Bank of Canada upped their price target on shares of ResMed from $181.00 to $182.00 and gave the company a “sector perform” rating in a report on Thursday, January 25th. UBS Group upped their price objective on shares of ResMed from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Needham & Company LLC upped their price objective on shares of ResMed from $215.00 to $224.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Mizuho restated a “buy” rating and issued a $215.00 price objective on shares of ResMed in a report on Wednesday, March 27th. Finally, Oppenheimer upped their price objective on shares of ResMed from $185.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, January 30th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $199.20.

ResMed Trading Down 2.2 %

NYSE:RMD opened at $189.51 on Thursday. The company has a fifty day moving average of $187.01 and a 200 day moving average of $168.98. ResMed has a 52 week low of $132.24 and a 52 week high of $243.52. The company has a quick ratio of 1.89, a current ratio of 3.11 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $27.88 billion, a P/E ratio of 31.32, a P/E/G ratio of 2.32 and a beta of 0.67.

Hedge Funds Weigh In On ResMed

Several institutional investors have recently made changes to their positions in RMD. Cambridge Investment Research Advisors Inc. raised its stake in ResMed by 15.7% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 3,050 shares of the medical equipment provider’s stock worth $740,000 after acquiring an additional 414 shares during the period. Cibc World Market Inc. raised its stake in ResMed by 13.0% during the 1st quarter. Cibc World Market Inc. now owns 1,000 shares of the medical equipment provider’s stock worth $243,000 after acquiring an additional 115 shares during the period. Vontobel Holding Ltd. raised its stake in ResMed by 14.5% during the 1st quarter. Vontobel Holding Ltd. now owns 8,112 shares of the medical equipment provider’s stock worth $2,020,000 after acquiring an additional 1,025 shares during the period. Sei Investments Co. raised its stake in ResMed by 7.8% during the 1st quarter. Sei Investments Co. now owns 40,740 shares of the medical equipment provider’s stock worth $9,781,000 after acquiring an additional 2,955 shares during the period. Finally, Prudential PLC bought a new stake in ResMed during the 1st quarter worth approximately $694,000. Institutional investors own 54.98% of the company’s stock.

Insider Activity at ResMed

In other news, General Counsel Michael J. Rider sold 200 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $173.25, for a total transaction of $34,650.00. Following the sale, the general counsel now owns 6,688 shares of the company’s stock, valued at approximately $1,158,696. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, General Counsel Michael J. Rider sold 200 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $173.25, for a total transaction of $34,650.00. Following the sale, the general counsel now owns 6,688 shares of the company’s stock, valued at approximately $1,158,696. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Peter C. Farrell sold 10,935 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the sale, the director now directly owns 157,404 shares in the company, valued at approximately $28,751,414.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,216 shares of company stock valued at $2,046,617. 1.21% of the stock is owned by insiders.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Thursday, February 8th were given a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 1.01%. The ex-dividend date of this dividend was Wednesday, February 7th. ResMed’s dividend payout ratio (DPR) is 31.74%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.